A number of firms have modified their ratings and price targets on shares of Stemline Therapeutics (NASDAQ: STML) recently:

  • 12/2/2018 – Stemline Therapeutics is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $12.26 price target on the stock.
  • 12/2/2018 – Stemline Therapeutics was given a new $33.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 11/29/2018 – Stemline Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 11/28/2018 – Stemline Therapeutics was given a new $38.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 11/26/2018 – Stemline Therapeutics is now covered by analysts at Piper Jaffray Companies. They set an “overweight” rating and a $20.00 price target on the stock.
  • 11/23/2018 – Stemline Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 11/23/2018 – Stemline Therapeutics was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/21/2018 – Stemline Therapeutics was given a new $38.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 11/16/2018 – Stemline Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 11/14/2018 – Stemline Therapeutics was given a new $33.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 11/12/2018 – Stemline Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $22.00 price target on the stock.
  • 11/12/2018 – Stemline Therapeutics was given a new $38.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 11/10/2018 – Stemline Therapeutics was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 11/8/2018 – Stemline Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 11/2/2018 – Stemline Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 10/24/2018 – Stemline Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.

Shares of NASDAQ:STML traded down $0.54 during midday trading on Wednesday, reaching $10.47. 943,956 shares of the company were exchanged, compared to its average volume of 335,271. Stemline Therapeutics Inc has a fifty-two week low of $10.00 and a fifty-two week high of $20.55. The firm has a market cap of $349.49 million, a price-to-earnings ratio of -3.56 and a beta of 0.64.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.06). Equities analysts predict that Stemline Therapeutics Inc will post -2.8 earnings per share for the current year.

In related news, COO Kenneth Hoberman sold 26,296 shares of the firm’s stock in a transaction on Monday, November 26th. The shares were sold at an average price of $11.85, for a total transaction of $311,607.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 14.80% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Los Angeles Capital Management & Equity Research Inc. bought a new position in Stemline Therapeutics in the second quarter valued at $398,000. Bank of America Corp DE grew its position in Stemline Therapeutics by 97.8% in the second quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock valued at $329,000 after purchasing an additional 10,159 shares in the last quarter. Nexthera Capital LP grew its position in Stemline Therapeutics by 6.9% in the second quarter. Nexthera Capital LP now owns 559,517 shares of the biopharmaceutical company’s stock valued at $8,980,000 after purchasing an additional 35,893 shares in the last quarter. Algert Global LLC bought a new position in Stemline Therapeutics in the second quarter valued at $344,000. Finally, Schwab Charles Investment Management Inc. grew its position in Stemline Therapeutics by 8.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 59,025 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 4,700 shares in the last quarter. 64.20% of the stock is owned by institutional investors and hedge funds.

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Recommended Story: What are the most popular ETFs

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.